249 related articles for article (PubMed ID: 25864113)
21. Ocular adnexal diffuse large B-cell lymphoma: a multicenter international study.
Munch-Petersen HD; Rasmussen PK; Coupland SE; Esmaeli B; Finger PT; Graue GF; Grossniklaus HE; Honavar SG; Khong JJ; McKelvie PA; Mulay K; Prause JU; Ralfkiaer E; Sjö LD; Sniegowski MC; Vemuganti GK; Heegaard S
JAMA Ophthalmol; 2015 Feb; 133(2):165-73. PubMed ID: 25393033
[TBL] [Abstract][Full Text] [Related]
22. [Clinical characteristics, cell origin and prognosis of primary gastrointestinal diffuse large B-cell lymphoma: a report of 40 cases].
Yang YL; Wang J; Zhao LZ; Gao ZF; Jing HM; Ke XY
Ai Zheng; 2008 Jun; 27(6):636-41. PubMed ID: 18570740
[TBL] [Abstract][Full Text] [Related]
23. Transcriptome sequencing reveals thousands of novel long non-coding RNAs in B cell lymphoma.
Verma A; Jiang Y; Du W; Fairchild L; Melnick A; Elemento O
Genome Med; 2015 Nov; 7():110. PubMed ID: 26521025
[TBL] [Abstract][Full Text] [Related]
24. The expression of CD30 based on immunohistochemistry predicts inferior outcome in patients with diffuse large B-cell lymphoma.
Hao X; Wei X; Huang F; Wei Y; Zeng H; Xu L; Zhou Q; Feng R
PLoS One; 2015; 10(5):e0126615. PubMed ID: 25974110
[TBL] [Abstract][Full Text] [Related]
25. The importance of Myd88 L265P mutation, clinical and immunohistochemical prognostic factors for the survival of patients with diffuse large B-cell non-Hodgkin lymphoma treated by immunochemotherapy in southeast Serbia.
Tadic L; Marjanovic G; Macukanovic-Golubovic L; Krstic M; Jevtovic-Stoimenov T; Kostov M; Smelcerovic Z; Stojanovic M
J BUON; 2016; 21(5):1259-1267. PubMed ID: 27837631
[TBL] [Abstract][Full Text] [Related]
26. Upregulation of nuclear transporter, Kpnβ1, contributes to accelerated cell proliferation- and cell adhesion-mediated drug resistance (CAM-DR) in diffuse large B-cell lymphoma.
He S; Miao X; Wu Y; Zhu X; Miao X; Yin H; He Y; Li C; Liu Y; Lu X; Chen Y; Wang Y; Xu X
J Cancer Res Clin Oncol; 2016 Mar; 142(3):561-72. PubMed ID: 26498772
[TBL] [Abstract][Full Text] [Related]
27. The biological and clinical impact of inhibition of NF-κB-initiated apoptosis in diffuse large B cell lymphoma (DLBCL).
Bavi P; Uddin S; Bu R; Ahmed M; Abubaker J; Balde V; Qadri Z; Ajarim D; Al-Dayel F; Hussain AR; Al-Kuraya KS
J Pathol; 2011 Jul; 224(3):355-66. PubMed ID: 21506127
[TBL] [Abstract][Full Text] [Related]
28. High miR-34a expression improves response to doxorubicin in diffuse large B-cell lymphoma.
Marques SC; Ranjbar B; Laursen MB; Falgreen S; Bilgrau AE; Bødker JS; Jørgensen LK; Primo MN; Schmitz A; Ettrup MS; Johnsen HE; Bøgsted M; Mikkelsen JG; Dybkær K
Exp Hematol; 2016 Apr; 44(4):238-46.e2. PubMed ID: 26854484
[TBL] [Abstract][Full Text] [Related]
29. Diffuse large B-cell lymphoma: clinical characterization and prognosis of Waldeyer ring versus lymph node presentation.
Qi SN; Li YX; Wang H; Wang WH; Jin J; Song YW; Wang SL; Liu YP; Zhou LQ; Yu ZH
Cancer; 2009 Nov; 115(21):4980-9. PubMed ID: 19634158
[TBL] [Abstract][Full Text] [Related]
30. Long non-coding RNAs expression levels in diffuse large B-cell lymphoma: An in silico analysis.
Dousti F; Shahrisa A; Ansari H; Hajjari M; Tahmasebi Birgani Y; Mohammadiasl J; Tahmasebi Birgani M
Pathol Res Pract; 2018 Sep; 214(9):1462-1466. PubMed ID: 30104077
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathological characteristics and genomic profile of primary sinonasal tract diffuse large B cell lymphoma (DLBCL) reveals gain at 1q31 and RGS1 encoding protein; high RGS1 immunohistochemical expression associates with poor overall survival in DLBCL not otherwise specified (NOS).
Carreras J; Kikuti YY; Beà S; Miyaoka M; Hiraiwa S; Ikoma H; Nagao R; Tomita S; Martin-Garcia D; Salaverria I; Sato A; Ichiki A; Roncador G; Garcia JF; Ando K; Campo E; Nakamura N
Histopathology; 2017 Mar; 70(4):595-621. PubMed ID: 27775850
[TBL] [Abstract][Full Text] [Related]
32. Clinical impact of serum survivin positivity and tissue expression of EBV-encoded RNA in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
Hong JY; Ryu KJ; Park C; Hong M; Ko YH; Kim WS; Kim SJ
Oncotarget; 2017 Feb; 8(8):13782-13791. PubMed ID: 28099151
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic strategy with artificially-designed i-lncRNA targeting multiple oncogenic microRNAs exhibits effective antitumor activity in diffuse large B-cell lymphoma.
Su Y; Sun B; Lin X; Zhao X; Ji W; He M; Qian H; Song X; Yang J; Wang J; Chen J
Oncotarget; 2016 Aug; 7(31):49143-49155. PubMed ID: 27172795
[TBL] [Abstract][Full Text] [Related]
34. Transcriptome profiling reveals an integrated mRNA-lncRNA signature with predictive value for long-term survival in diffuse large B-cell lymphoma.
Gao Q; Li Z; Meng L; Ma J; Xi Y; Wang T
Aging (Albany NY); 2020 Nov; 12(22):23275-23295. PubMed ID: 33221755
[TBL] [Abstract][Full Text] [Related]
35. [Influence of transplantation and some clinical factors on prognosis of patients with diffuse large B-cell lymphoma].
Zhao SX; Han Y; Zhu Q; Wang Q; Zhang WJ; Chen XC; Sun AN; Jin ZM; Qiu HY; Tang XW; Fu ZZ; He GS; Miao M; Ma X; Wu DP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):623-7. PubMed ID: 23815910
[TBL] [Abstract][Full Text] [Related]
36. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
[TBL] [Abstract][Full Text] [Related]
37. Prediction of relapse and prognosis by expression levels of long noncoding RNA PEG10 in glioma patients.
Xiao H; Ding N; Liao H; Yao Z; Cheng X; Zhang J; Zhao M
Medicine (Baltimore); 2019 Nov; 98(45):e17583. PubMed ID: 31702614
[TBL] [Abstract][Full Text] [Related]
38. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z
Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255
[TBL] [Abstract][Full Text] [Related]
39. Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial.
Johnston PB; LaPlant B; McPhail E; Habermann TM; Inwards DJ; Micallef IN; Colgan JP; Nowakowski GS; Ansell SM; Witzig TE
Lancet Haematol; 2016 Jul; 3(7):e309-16. PubMed ID: 27374464
[TBL] [Abstract][Full Text] [Related]
40. ICT1 predicts a poor survival and correlated with cell proliferation in diffuse large B-cell lymphoma.
Xie W; Wu M; Fu T; Li X; Wang Z; Hu Y; Zhu L; Zhang G
Gene; 2017 Sep; 627():255-262. PubMed ID: 28629825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
